Aktis Oncology, Inc. (AKTS) vs Janux Therapeutics, Inc. (JANX)
A side-by-side comparison of Aktis Oncology, Inc. and Janux Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.47HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
JANX
Janux Therapeutics, Inc.
$16.39HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
Total return — AKTS vs JANX
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)JANX +16.8% (+16.8%/yr)JANX compounded faster over this window
AKTS JANX
AKTS vs JANX: by the numbers
- •JANX is the larger company ($999M vs $986M market cap).
- •Both run net losses; JANX's is the smaller (-321.81% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | JANX |
|---|---|---|
| P/S ratio | 98.04 | 31.34 |
| P/B ratio | 2.03 | 1.08 |
Profitability
| Metric | AKTS | JANX |
|---|---|---|
| Gross margin | 100.00% | 79.71% |
| Operating margin | -1149.52% | -1576.67% |
| Net margin | -727.04% | -321.81% |
| ROE | -15.09% | -11.06% |
| ROIC | -16.54% | -15.15% |
Growth (annualized)
| Metric | AKTS | JANX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 105.89% |
| Total return CAGR (5Y) | N/A | -6.45% |
Go deeper
Dig into the metrics
Aktis Oncology ROEJanux Therapeutics ROEAktis Oncology operating marginJanux Therapeutics operating marginAktis Oncology revenue growthJanux Therapeutics revenue growthAktis Oncology free cash flowJanux Therapeutics free cash flow
Aktis Oncology & Janux Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.